{
  "profile_url": "https://www.moffitt.org/research-science/researchers/nikhil-khushalani/",
  "last_updated": "2025-11-21T22:50:26.155942",
  "researcher_id": "16108",
  "degrees": [
    "MD"
  ],
  "title": "",
  "primary_program": "cutaneous oncology",
  "research_program": "molecular medicine",
  "overview": "Dr. Khushalani is interested in research on angiogenesis in melanoma and the translation of findings into clinical therapeutics.",
  "research_interests": [
    "He is studying the economic impact of new melanoma drugs on healthcare (pharmacoeconomics) with an aim to devise strategies to reduce cost.\n  *"
  ],
  "associations": [
    "Cutaneous Oncology",
    "Molecular Medicine Program",
    "Melanoma & Skin Cancer Center of Excellence"
  ],
  "education": [
    {
      "type": "Medical School",
      "institution": "T.N. Medical College University of Bombay"
    },
    {
      "type": "Residency",
      "institution": "KEM Hospital and Seth GS Medical Collage",
      "position": "Intern",
      "specialty": "al Medicine"
    },
    {
      "type": "Residency",
      "institution": "State University of New York",
      "position": "Intern",
      "specialty": "al Medicine"
    },
    {
      "type": "Fellowship",
      "institution": "Roswell Park Cancer Institute",
      "specialty": "Medical Oncology"
    },
    {
      "type": "Board Certification",
      "institution": "Internal Medicine",
      "certification": "Medical Oncology"
    }
  ],
  "publications": [
    {
      "title": "Cancer-induced nerve injury promotes resistance to anti-PD-1 therapy",
      "pubmed_id": "40836096",
      "pmc_id": "PMC12406299",
      "year": "2025",
      "publication_date": "2025 Oct",
      "authors": "Baruch EN, Gleber-Netto FO, Nagarajan P, Rao X, Akhter S, Eichwald T, Xie T, Balood M, Adewale A, Naara S, Sathishkumar HN, Islam S, McCarthy W, Mattson BJ, Ferrarotto R, Wong MK, Davies MA, Jindal S, Basu S, Roversi K, Nikpoor AR, Ahmadi M, Ahmadi A, Harwood C, Leigh I, Gong D, Tall\u00f3n de Lara P, Tao DL, Davidson TM, Ajami NJ, Futreal A, Rai K, Kochat V, Castillo M, Gunaratne P, Goepfert RP, Hernandez SD, Khushalani NI, Wang J, Watowich SS, Calin GA, Migden MR, Yuan M, Liu N, Ye Y, Hwang WL, Vermeer PD, D'Silva NJ, Bunimovich YL, Yaniv D, Burks JK, Gomez J, Dougherty PM, Tsai KY, Allison JP, Sharma P, Wargo JA, Myers JN, Talbot S, Gross ND, Amit M",
      "journal": "Nature"
    },
    {
      "title": "Recurrence and Survival Outcomes in Patients with Primary Merkel Cell Carcinoma with Positive, Negative, or Not Performed Sentinel Lymph Node Biopsy",
      "pubmed_id": "41168606",
      "year": "2025",
      "publication_date": "2025 Oct",
      "authors": "Dugan MM, Balsay-Patel C, Chin N, Israeli J, Ward KR, Nichols M, Greenbaum S, Fan W, Cruse CW, Harrington M, Neves RI, Gonzalez RJ, Perez MC, Sarnaik AA, Sondak VK, Messina JL, Tarhini AA, Khushalani N, Brohl AS, Markowitz J, Eroglu Z, Karapetyan L, Tsai KY, Zager JS",
      "journal": "Ann Surg Oncol"
    },
    {
      "title": "Phase II Trial of Pembrolizumab in Combination With Bevacizumab for Untreated Melanoma Brain Metastases",
      "pubmed_id": "40048689",
      "pmc_id": "PMC12058415",
      "year": "2025",
      "publication_date": "2025 May",
      "authors": "Weiss SA, Djureinovic D, Wei W, Tran T, Austin M, Markowitz J, Eroglu Z, Khushalani NI, Hegde U, Cohen J, Sznol M, Anderson G, Johnson B, Piteo C, Mahajan A, Adeniran A, Jilaveanu L, Goldberg S, Chiang V, Forsyth P, Kluger HM",
      "journal": "J Clin Oncol"
    },
    {
      "title": "Protected Time, Resources, and Expectations for Academic Oncology Clinical Research Physicians",
      "pubmed_id": "40645220",
      "year": "2025",
      "publication_date": "2025 Jul",
      "authors": "Gerber DE, Khushalani NI, Gao A, Zhang S, Clark JW, Messersmith WA, Benson AB, Puzanov I, Hayes DN, Zion NA, Heinrichs T, Berlin JD",
      "journal": "J Natl Compr Canc Ne"
    },
    {
      "title": "A phase 2 open-label study of cemiplimab in patients with advanced cutaneous squamous cell carcinoma (EMPOWER-CSCC-1): Final long-term analysis of groups 1, 2, and 3, and primary analysis of fixed-dose treatment group 6",
      "pubmed_id": "39245360",
      "year": "2025",
      "publication_date": "2025 Jan",
      "authors": "Hughes BGM, Guminski A, Bowyer S, Migden MR, Schmults CD, Khushalani NI, Chang ALS, Grob JJ, Lewis KD, Ansstas G, Day F, Ladwa R, Stein BN, Mu\u00f1oz Couselo E, Meier F, Hauschild A, Schadendorf D, Basset-Seguin N, Modi B, Dalac-Rat S, Dunn LA, Flatz L, Mortier L, Gu\u00e9gan S, Heinzerling LM, Mehnert JM, Trabelsi S, Soria-Rivas A, Stratigos AJ, Ulrich C, Wong DJ, Beylot-Barry M, Bossi P, Bug\u00e9s S\u00e1nchez C, Chandra S, Robert C, Russell JS, Silk AW, Booth J, Yoo SY, Seebach F, Lowy I, Fury MG, Rischin D",
      "journal": "J Am Acad Dermatol"
    },
    {
      "title": "CASE (CemiplimAb-rwlc Survivorship and Epidemiology): a study in advanced basal cell carcinoma",
      "pubmed_id": "39797702",
      "pmc_id": "PMC11812358",
      "year": "2025",
      "publication_date": "2025 Feb",
      "authors": "Park SJ, Ellison DM, Weight R, Homsi J, Rabinowits G, Ruiz ES, Strasswimmer J, Simmons J, Panella T, Quek RG, Pouliot JF, Khushalani NI",
      "journal": "Future Oncol"
    },
    {
      "title": "Publisher Correction: Anti-PD-1 therapy in unresectable desmoplastic melanoma: the phase 2 SWOG S",
      "pubmed_id": "40858972",
      "year": "1512",
      "publication_date": "1512 trial",
      "authors": "Kendra KL, Bellasea SL, Eroglu Z, Hu-Lieskovan S, Campbell KM, Carson WE, Wada DA, Plaza JA, Sosman JA, In GK, Ikeguchi A, Hyngstrom J, Brohl AS, Khushalani NI, Markowitz J, Negrea G, Kasbari S, Doolittle GC, Swami U, Roberts T, Mathew BN, Medina E, Baselga-Carretero I, Gonzalez CR, Garcilazo IP, Vega-Crespo A, Chen JM, Naser Al-Deen N, Patel SP, Sharon E, Moon J, Wu MC, Ribas A"
    },
    {
      "title": "Adjuvant Cemiplimab or Placebo in High-Risk Cutaneous Squamous-Cell Carcinoma",
      "pubmed_id": "40454639",
      "year": "2025",
      "publication_date": "2025 Aug",
      "authors": "Rischin D, Porceddu S, Day F, Brungs DP, Christie H, Jackson JE, Stein BN, Su YB, Ladwa R, Adams G, Bowyer SE, Otty Z, Yamazaki N, Bossi P, Challapalli A, Hauschild A, Lim AM, Patel VA, Walker JL, De Liz Vassen Schurmann M, Queirolo P, Ca\u00f1ueto J, Ferreira da Silva FA, Stratigos A, Guminski A, Lin C, Damian F, Flatz L, Taylor AE, Carr DR, Harris S, Kirtbaya D, Quereux G, Rutkowski P, Basset-Seguin N, Khushalani NI, Robert C, Ju H, Joseph C, Bansal S, Chen CI, Seebach F, Yoo SY, Lowy I, Goncalves P, Fury MG",
      "journal": "N Engl J Med"
    },
    {
      "title": "Durability of response to immune checkpoint blockade following treatment discontinuation and efficacy of rechallenge in advanced Merkel cell carcinoma",
      "pubmed_id": "39242118",
      "pmc_id": "PMC11381633",
      "year": "2024",
      "publication_date": "2024 Sep",
      "authors": "Ramadoss T, Nichols M, Palacios C, Eroglu Z, Markowitz J, Karapetyan L, Tarhini AA, Wuthrick EJ, Sondak VK, Khushalani NI, Tsai KY, Brohl AS",
      "journal": "J Immunother Cancer"
    },
    {
      "title": "Preexisting Skin-Resident CD8 and \u03b3\u03b4 T-cell Circuits Mediate Immune Response in Merkel Cell Carcinoma and Predict Immunotherapy Efficacy",
      "pubmed_id": "39058036",
      "year": "2024",
      "publication_date": "2024 Sep",
      "authors": "Reinstein ZZ, Zhang Y, Ospina OE, Nichols MD, Chu VA, Pulido AM, Prieto K, Nguyen JV, Yin R, Moran Segura C, Usman A, Sell B, Ng S, de la Iglesia JV, Chandra S, Sosman JA, Cho RJ, Cheng JB, Ivanova E, Koralov SB, Slebos RJC, Chung CH, Khushalani NI, Messina JL, Sarnaik AA, Zager JS, Sondak VK, Vaske C, Kim S, Brohl AS, Mi X, Pierce B, Wang X, Fridley BL, Tsai KY, Choi J",
      "journal": "Cancer Discov"
    }
  ],
  "grants": [
    {
      "description": "Title: SWOG Network Group Operations Center of the NCTN  \nAward Number: U10CA180888  \nSponsor: University of California, Davis  \nKhushalani, N. (PD/PI)",
      "title": "SWOG Network Group Operations Center of the NCTN",
      "award_number": "U10CA180888",
      "sponsor": "University of California, Davis",
      "investigators": [
        {
          "name": "Khushalani, N.",
          "role": "PD/PI"
        }
      ]
    },
    {
      "description": "Title: SWOG Network Group Operators Center of the NCTN  \nAward Number: 5U01CA180888-07  \nSponsor: National Cancer Institute (NCI)  \nKhushalani, N. (PD/PI)",
      "title": "SWOG Network Group Operators Center of the NCTN",
      "award_number": "5U01CA180888-07",
      "sponsor": "National Cancer Institute (NCI)",
      "source": "NCI",
      "investigators": [
        {
          "name": "Khushalani, N.",
          "role": "PD/PI"
        }
      ]
    }
  ],
  "participating_trials": [
    {
      "trial_url": "https://www.moffitt.org/clinical-trials-and-studies/clinical-trial-19868/",
      "trial_id": "19868",
      "title": "First in Human Phase I Study of 225Actinium-DOTA-Ahx-MC1RL (225Ac-MTI-201) in Metastatic Melanoma",
      "condition": "Cutaneous",
      "intervention": "225Ac-MTI-201 ()",
      "status": "Open"
    },
    {
      "trial_url": "https://www.moffitt.org/clinical-trials-and-studies/clinical-trial-21731/",
      "trial_id": "21731",
      "title": "A Phase II Trial of Olaparib in Combination with Pembrolizumab for Advanced Uveal Melanoma",
      "condition": "Cutaneous",
      "intervention": "Olaparib (Lynparza); Pembrolizumab (Keytruda)",
      "status": "OPEN (SUSPENDED)"
    },
    {
      "trial_url": "https://www.moffitt.org/clinical-trials-and-studies/clinical-trial-21996/",
      "trial_id": "21996",
      "title": "An Open-Label, Multicenter, Phase 1b/2 Study of RP1 in Solid Organ Transplant Recipients with Advanced Cutaneous Malignancies",
      "condition": "Cutaneous",
      "intervention": "RP1 ()",
      "status": "Open"
    },
    {
      "trial_url": "https://www.moffitt.org/clinical-trials-and-studies/clinical-trial-23116/",
      "trial_id": "23116",
      "title": "IDE196 (Darovasertib) In Combination with Crizotinib Versus Investigators Choice of Treatment as First-Line Therapy In HLA-A2 Negative Metastatic Uveal Melanoma (Dar-Um-2)",
      "condition": "Cutaneous",
      "intervention": "BMS-936558 (Nivolumab); Crizotinib (); IDE196 (); Ipilimumab (); Nivolumab (Opdivo); Pembrolizumab (Keytruda); Xalkori (Crizotinib); Yervoy (Ipilimumab)",
      "status": "Open"
    },
    {
      "trial_url": "https://www.moffitt.org/clinical-trials-and-studies/clinical-trial-23341/",
      "trial_id": "23341",
      "title": "A Randomized, Controlled, Multicenter, Phase 3 Clinical Study Comparing Vusolimoqene Oderparepvec in Combination with Nivolumab Versus Treatment of Physician's Choice in Patients with Advanced Melanoma that Has Progressed on an Anti-PD-1 and an Anti-CTLA-4 Containing Treatment Regimen",
      "condition": "Cutaneous",
      "intervention": "Albumin-Bound Paclitaxel (); BMS-936558 (Nivolumab); BMS-986016 (Relatlimab); DTIC (Dacarbazine); Dacarbazine (); Nivolumab (Opdivo); Pembrolizumab (Keytruda); Relatlimab (); Taxol (paclitaxel); Temodal (Temozolomide); Temozolomide (); Vusolimogene Oderparepvec (); paclitaxel ()",
      "status": "Open"
    },
    {
      "trial_url": "https://www.moffitt.org/clinical-trials-and-studies/clinical-trial-23377/",
      "trial_id": "23377",
      "title": "A Phase 3 Study of Fixed Dose Combinations of Fianlimab and Cemiplimab versus Relatlimab and Nivolumab in Participants with Unresectable or Metastatic Melanoma.",
      "condition": "Cutaneous",
      "intervention": "BMS-936558 (Nivolumab); BMS-986016 (Relatlimab); Cemiplimab (); Fianlimab (); Nivolumab (Opdivo); REGN2810 (Cemiplimab); Relatlimab ()",
      "status": "Open"
    }
  ],
  "lab_page_url": "",
  "google_scholar_url": "",
  "photo_url": "https://www.moffitt.org/globalassets/images/researchers_bio/KhushalaniNikhil_16108.jpg",
  "contact": {
    "contact_url": "https://eforms.moffitt.org/ContactResearchersForm?PERID=16108"
  },
  "content_hash": "58c9b2f5c825e668db0575921fc856bf7c2ab46caf92226aa58fc95c78771982",
  "researcher_name": "nikhil khushalani",
  "department": ""
}